Drugs / Adenovirus-transfected DC
Adenovirus-transfected DC
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01924156 | Jul 2013 → Dec 2016 | renal cell carcinoma | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT01898663 | Jun 2013 → Dec 2024 | soft tissue sarcoma | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adenovirus-transfected DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01898663 ↗ |
| Known as | Adenovirus-transfected autologous DC vaccine | “Adenovirus-transfected autologous DC vaccine plus CIK cells” NCT01898663 ↗ |
| Known as | DC vaccine | “adenovirus-transfected DC vaccine plus CIK cells” NCT01924156 ↗ |
| Modality | Vaccine | “DCs vaccine” NCT01898663 ↗ |